This study focuses on the detection of infection sources in dynamic networks,which is very important for network analysis,cybersecurity,and public health.We aim to improve source detection in complex networks using da...This study focuses on the detection of infection sources in dynamic networks,which is very important for network analysis,cybersecurity,and public health.We aim to improve source detection in complex networks using data,computational advances,and machine learning to improve epidemic response and public health protection.We explore dynamic network analysis and recent algorithms for infection source detection,emphasizing data integration and machine learning.Our approach involves reviewing existing research,identifying gaps,and proposing dynamic network-based infectious disease source detection strategies.Our study highlights evolving infection source detection methods and underscores the potential of machine learning and artificial intelligence.We acknowledge ongoing challenges due to network complexity and outline promising research directions.Detecting infection sources in dynamic networks is vital.This study emphasizes the need for improved techniques and technology integration to address complexities effectively.Advancements will empower us to identify and mitigate epidemics,reducing their societal and public health impacts.展开更多
The treatment of chronic lymphocytic leukaemia has been revolutionised in recent years,first by the introduction of chemoimmunotherapy regimens and subsequently by the development of drugs,including ibrutinib,idelalis...The treatment of chronic lymphocytic leukaemia has been revolutionised in recent years,first by the introduction of chemoimmunotherapy regimens and subsequently by the development of drugs,including ibrutinib,idelalisib and venetoclax,that target components of the B-cell receptor signalling pathway or B-cell lymphoma 2 family of proteins.Despite high initial response rates in patients treated with chemoimmunotherapy or targeted agents,a significant proportion of patients relapse with progressive and refractory disease.In a subset of these patients,drug resistance has been associated with specific genetic lesions or activation of alternate pro-survival pathways.However,the mechanisms that confer drug resistance in the remainder of the patients with refractory disease have yet to be fully elucidated.In this review,we discuss our current understanding of the mechanics of drug resistance in chronic lymphocytic leukaemia and describe how this knowledge may aid in rationalising future treatment strategies to prevent the development of refractory or aggressive transformation of the disease.展开更多
文摘This study focuses on the detection of infection sources in dynamic networks,which is very important for network analysis,cybersecurity,and public health.We aim to improve source detection in complex networks using data,computational advances,and machine learning to improve epidemic response and public health protection.We explore dynamic network analysis and recent algorithms for infection source detection,emphasizing data integration and machine learning.Our approach involves reviewing existing research,identifying gaps,and proposing dynamic network-based infectious disease source detection strategies.Our study highlights evolving infection source detection methods and underscores the potential of machine learning and artificial intelligence.We acknowledge ongoing challenges due to network complexity and outline promising research directions.Detecting infection sources in dynamic networks is vital.This study emphasizes the need for improved techniques and technology integration to address complexities effectively.Advancements will empower us to identify and mitigate epidemics,reducing their societal and public health impacts.
文摘The treatment of chronic lymphocytic leukaemia has been revolutionised in recent years,first by the introduction of chemoimmunotherapy regimens and subsequently by the development of drugs,including ibrutinib,idelalisib and venetoclax,that target components of the B-cell receptor signalling pathway or B-cell lymphoma 2 family of proteins.Despite high initial response rates in patients treated with chemoimmunotherapy or targeted agents,a significant proportion of patients relapse with progressive and refractory disease.In a subset of these patients,drug resistance has been associated with specific genetic lesions or activation of alternate pro-survival pathways.However,the mechanisms that confer drug resistance in the remainder of the patients with refractory disease have yet to be fully elucidated.In this review,we discuss our current understanding of the mechanics of drug resistance in chronic lymphocytic leukaemia and describe how this knowledge may aid in rationalising future treatment strategies to prevent the development of refractory or aggressive transformation of the disease.
